Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001998 | 0.89 | CA2 (0.43) | SMN1; SMN2CA2CA1HDAC1KMT2A | |
| SCHEMBL10002003 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2CA2CA1HDAC1KMT2A | |
| SCHEMBL863060 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2CA2CA1HDAC1HDAC3 | |
| SCHEMBL864270 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2CA2CA1HDAC1KMT2A | |
| SCHEMBL10001999 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2CA2CA1HDAC1HDAC3 | |
| SCHEMBL863113 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2HDAC1KMT2AHDAC3MCHR1 | |
| SCHEMBL8846821 | 0.74 | MEN1 (0.56) | SMN1; SMN2CA2CA1HDAC1KMT2A | |
| SCHEMBL29205214 | 0.74 | ALDH1A1 (0.50) | SMN1; SMN2HDAC1KMT2AHDAC3MCHR1 | |
| SCHEMBL3641810 | 0.74 | HDAC1 (0.56) | SMN1; SMN2CA2CA1HDAC1KMT2A | |
| SCHEMBL30002337 | 0.73 | NAAA (0.52) | SMN1; SMN2CA2HDAC1KMT2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8120893-B2 | Tether-containing conducting polymers | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100073847-A1 | TETHER-CONTAINING CONDUCTING POLYMERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100073847-A1 | TETHER-CONTAINING CONDUCTING POLYMERS | SPIN4, PAH, SMC4 | SMN1; SMN2 2798/4885CA2 688/4885CA1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.